Press Releases Archives | Page 58 of 65

RoosterBio Launches New cGMP Stem Cell Product Portfolio

September 14, 2017 By Cade Hildreth (CEO) Leave a Comment

RoosterBio Launches New cGMP Stem Cell Product Portfolio, Maintaining Unwavering Commitment to Driving the Explosive Regenerative Medicine Industry

Next Generation Products are Harbinger of Paradigm Shift in the Adult Stem Cell Industry

Frederick, MD, USA. September 14, 2017 – RoosterBio Inc, today, proudly announces the launch of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary materials that generate unprecedented efficiencies in adult stem cell manufacturing, accelerating clinical translation of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio will radically simplify major steps in product development and clinical translation, improving the likelihood of commercial success for RoosterBio customers.

The first in the CliniControl line of products, RoosterNourish™-MSC-CC bioprocess medium sets the new standard of industry-leading performance. RoosterNourish-MSC-CC is a first-in-class, standardized, xeno-free (XF) bioprocess medium engineered to support not only 2D (plastic adherent), but also 3D suspension culture of hMSCs in allogeneic and autologous therapeutic manufacturing. Formulated specifically for clinical research process and product developers, RoosterNourish-MSC-CC yields superior media productivity, leading to drastically reduced cost of goods as compared to other hMSC culture media. The highly productive RoosterNourish medium is designed for batch 2D and fed-batch 3D cultures and seamlessly translates between culture platforms enabling scalable hMSC culture, delivering robust, reproducible and standardized results at a commercially-viable cost of goods. [Read more…]

LifeCell Becomes India’s Biggest Cord Blood Stem Cell Registry for Unrelated Use

September 9, 2017 By Cade Hildreth (CEO) Leave a Comment

Achieves landmark milestone within four months of launch of revolutionary banking model

CHENNAI, August 7, 2017 – In spite of being a highly populated country, India has lacked availability of donor cord blood samples and registered bone marrow donors. The number of cord blood units preserved with public banks in India is collectively around 5,000. The probability of finding a matching unit from this small inventory is low, leaving over 70% of Indian patients requiring donor stem cells in the lurch. According to an ICMR study only when the inventory increases to >250,000 would almost every patient find a match. [Read more…]

Donor Egg Bank to Provide Free Cord Blood Processing through FamilyCord

August 5, 2017 By Cade Hildreth (CEO) Leave a Comment

World’s Largest Frozen Egg Bank offers a Lifetime of Security

Rockville, MD, Aug. 1, 2017— Donor Egg Bank, a California Cryobank company, continues to set the standard for the frozen donor egg industry by offering a truly once in lifetime opportunity to their intended parents – free processing for their future babies’ cord blood stem cells through sister company FamilyCord – a $1,500 savings.

[Read more…]

AgeX Therapeutics Obtains $10 Million in Capital and Commences Operations

August 2, 2017 By Cade Hildreth (CEO) Leave a Comment

August 02, 2017, ALAMEDA, Calif.–AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE MKT: BTX), today reported that it has successfully raised $10 million in equity financing to fund its operations. Following the financing, BioTime continues to own about 87% of AgeX’s outstanding shares. The financing is expected to fund preclinical development at AgeX as well as building the company’s operational infrastructure. The financing may also lead to a registration and distribution of a to-be-determined percentag of the AgeX shares to BioTime shareholders, after which AgeX would trade as a public company. [Read more…]

Capricor Announces Results of FDA Meeting on Intravenous CAP-1002 for Duchenne Muscular Dystrophy

July 27, 2017 By Cade Hildreth (CEO) Leave a Comment

LOS ANGELES, July 27, 2017 — Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy (DMD) and other rare diseases, today announced that it has received official minutes of the meeting held recently between the U.S. Food and Drug Administration (FDA) and Capricor to discuss the development of intravenous CAP-1002 (allogeneic cardiosphere-derived cells) for the treatment of Duchenne muscular dystrophy (DMD).